PDT Partners LLC Reduces Holdings in Qiagen N.V. $QGEN

Key Points

• PDT Partners LLC reduced its holdings in Qiagen N.V. by 55.7% in the first quarter, bringing their total shares to 45,607 valued at approximately $1.83 million.
• Several institutional investors made moves in Qiagen stock, with SVB Wealth LLC and ANTIPODES PARTNERS Ltd initiating new positions valued at $31,000 and $94,000 respectively.
• Qiagen's earnings per share met analysts' expectations at $0.60 for the quarter, along with a revenue of $533.54 million, indicating a 7.7% increase year over year.

PDT Partners LLC reduced its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 55.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,607 shares of the company's stock after selling 57,436 shares during the period. PDT Partners LLC's holdings in Qiagen were worth $1,831,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. Exchange Traded Concepts LLC grew its stake in Qiagen by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after purchasing an additional 395 shares during the period. SVB Wealth LLC acquired a new position in Qiagen in the 1st quarter worth about $31,000. Walleye Trading LLC lifted its holdings in Qiagen by 14.6% in the first quarter. Walleye Trading LLC now owns 7,367 shares of the company's stock valued at $296,000 after acquiring an additional 936 shares during the last quarter. Cetera Investment Advisers lifted its stake in Qiagen by 14.4% during the fourth quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock worth $505,000 after purchasing an additional 1,418 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after buying an additional 1,425 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Stock Performance

QGEN remained flat at $47.55 during midday trading on Monday. 260,685 shares of the company's stock were exchanged, compared to its average volume of 1,386,231. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $10.57 billion, a PE ratio of 28.10, a PEG ratio of 2.51 and a beta of 0.64. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88. The business's 50-day moving average price is $48.65 and its 200-day moving average price is $44.42.

Qiagen (NYSE:QGEN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts' consensus estimates of $0.60. The business had revenue of $533.54 million for the quarter, compared to analyst estimates of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. Qiagen's revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Cowen reiterated a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. UBS Group lifted their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Wall Street Zen downgraded shares of Qiagen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Barclays initiated coverage on shares of Qiagen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Finally, Bank of America raised their target price on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Three research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.